禾元生物：公司将持续加强与投资者的合法合规沟通

Core Viewpoint - He Yuan Bio stated that it cannot disclose specific information regarding product sales, market feedback, new drug approval progress, medical insurance access plans, and 2025 annual report performance due to the sensitive nature of this information [1] Group 1 - The company emphasized that disclosing such information prematurely or in a non-standard manner could violate the principle of information disclosure fairness and potentially impact the trading order of the securities market [1] - He Yuan Bio plans to enhance communication with investors through regular reports and performance briefings to address reasonable concerns [1]